SCHEMBL24038488

SCHEMBL24038488

Cc1cc2c(F)cc(F)cc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
TRPA1 O75762 1/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.35
KIF11 P52732 1/20 0.35
EIF4A3 P38919 1/20 0.35
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
GAA P10253 3/20 0.34
RXFP1 Q9HBX9 2/20 0.34
CYP1A2 P05177 2/20 0.34
MEN1 O00255 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22408290 0.83 KEAP1 (0.43) KEAP1NFE2L2MAPTLMNAKIF11
SCHEMBL29445923 0.83 KEAP1 (0.43) KEAP1NFE2L2MAPTLMNAKIF11
SCHEMBL22408525 0.79 KEAP1 (0.41) KEAP1NFE2L2MAPTLMNAKIF11
SCHEMBL21624065 0.79 KEAP1 (0.41) KEAP1NFE2L2MAPTLMNAKIF11
SCHEMBL19966505 0.79 LMNA (0.41) KEAP1NFE2L2MAPTLMNAKIF11
SCHEMBL26262427 0.78 MEN1 (0.37) KIF11EIF4A3MEN1KMT2AHPGD
SCHEMBL22407975 0.76 KEAP1 (0.39) KEAP1NFE2L2MAPTRXFP1MEN1
SCHEMBL25134300 0.76 KEAP1 (0.39) KEAP1NFE2L2MAPTLMNAKIF11
SCHEMBL29445889 0.76 KEAP1 (0.39) KEAP1NFE2L2MAPTRXFP1MEN1
SCHEMBL24038455 0.76 KEAP1 (0.39) KEAP1NFE2L2MAPTLMNAKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
WO-2023055702-A1 MAIN PROTEASE (M PRO) INHIBITORS AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-04-06 WO disclosed
WO-2021250461-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-12-16 WO disclosed
WO-2021229302-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 KEAP1 1700/4885NFE2L2 1761/4885TRPA1 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.